Publications by authors named "Dan Vogl"

Claim this Profile
O
Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma.
Heta Patel, Harper Hubbeling, Kyle L Yu, Maribel Carpenter, Michael J LaRiviere, Dan T Vogl

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.
Taxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl, Sarah E Gibson, Meaghen E Sharik

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of relapse after teclistamab therapy in multiple myeloma.
Kyle L Yu, Matthew Ho, Luca Paruzzo, Federico Stella, Heta Patel, Dan T Vogl

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.
Sarah A Holstein, Shebli Atrash, Hira Mian, Meletios A Dimopoulos, Fredrik Schjesvold, Dan T Vogl

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma.
Matthew Ho, Luca Paruzzo, Janna Minehart, Teja Voruganti, Pooja Devi, Dan T Vogl

Haematologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic, Dan Vogl

J Natl Compr Canc Netw· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.
Rahul Banerjee, Amber R Fritz, Othman S Akhtar, Ciara L Freeman, Andrew J Cowan, Dan T Vogl

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis.
Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T Vogl, Mia Djulbegovic

Eur J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.
Mahmoud R Gaballa, Omar Castaneda Puglianini, Adam Cohen, Dan Vogl, Alfred Chung

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.
Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don Benson

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.
Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen, Dan Vogl

Bone Marrow Transplant· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil extracellular traps promote tumor chemoresistance to anthracyclines.
Cindy Lin, Sarah E Herlihy, Marina Li, Hui Deng, Rina Kim, Dan T Vogl

bioRxiv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario, Dan T Vogl

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice.
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, Leonard D Shultz, Yan Tang, Dan T Vogl

JCI Insight· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette, Dan T Vogl

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.
Yan Tang, Wei Liu, Siddhant Kadu, Omar Johnson, Zainul S Hasanali, Dan T Vogl

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice.
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, Leonard D Shultz, Yan Tang, Dan T Vogl

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Alfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, Wei-Ting Hwang, Dan T Vogl

Blood Cancer Discov· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive multifocal leukoencephalopathy in multiple myeloma.
Brian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, Sandra P Susanibar-Adaniya, Dan T Vogl

Eur J Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes.
Cindy Lin, Laura Garcia-Gerique, Erin E Bonner, Jerome Mastio, Matthew Rosenwasser, Thomas Vogl, Dan T Vogl

Cancer Res Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Mark A Dawson, Gautam Borthakur, Brian J P Huntly, Anastasios Karadimitris, Adrian Alegre, Dan T Vogl

Clin Cancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression.
Hui Deng, Cindy Lin, Laura Garcia-Gerique, Shuyu Fu, Zachary Cruz, Dan T Vogl

Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Robert Frank Cornell, Rachid Baz, Joshua R Richter, Adriana Rossi, Dan T Vogl

Am J Hematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).
Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, Beth Blackwell, Paul K Wallace, Dan T Vogl

Blood Cancer J· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy.
Alfred Garfall, Adam Cohen, Edward Stadtmauer, Sandra Susanibar-Adaniya, Dan Vogl

J Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis